Welcome!

News Feed Item

AgeneBio Appoints Industry Leaders Patrick LePore as Chairman of the Board and Jerry McLaughlin as President and Chief Executive Officer

Appointments Complete Leadership Team to Advance Development Programs Including a Product Candidate in Phase II/III to Slow the Progression of Alzheimer's Disease

BALTIMORE, MD -- (Marketwired) -- 07/25/14 -- AgeneBio, Inc., a clinical-stage pharmaceutical company developing medicines to restore and preserve patients' cognitive function for a range of debilitating neurodegenerative diseases, today announced the appointment of Patrick LePore as chairman of the board and Jerry McLaughlin as president and chief executive officer. Both appointments are effective immediately.

"Pat and Jerry are distinguished leaders in the pharmaceutical industry and will play integral roles in the development and commercialization of the AgeneBio portfolio by providing strategic guidance as we continue to advance our product pipeline," says Dr. Michela Gallagher, founder and chief scientific officer of AgeneBio.

Mr. LePore has over 30 years of experience in the pharmaceutical industry, most recently as Chairman, CEO and President of Par Pharmaceuticals where he guided the company to a sale to Texas Pacific Group. His industry experience spans both the private and public sectors with board and operational experience in each, making him one of a handful of pharmaceutical executives with in depth knowledge of the brand, generic and pharmaceutical service industries.

"The development of a therapeutic to transform the management of Alzheimer's disease is desperately needed and yet potentially within reach, and I'm thrilled at the prospect of helping AgeneBio achieve that goal," said LePore.

Prior to joining AgeneBio, Mr. McLaughlin served as senior vice president and chief commercial officer of NuPathe Inc. through the company's sale to Teva Pharmaceuticals Industries Ltd. in 2014. At NuPathe, McLaughlin was responsible for preparing the organization for commercialization. In addition, he played an integral role in raising capital, including an initial public offering and corporate development initiatives that led to acquisition by Teva in a competitive M&A process. He has also held a variety of commercial leadership roles at Merck and Endo Pharmaceuticals with extensive experience launching new products, including several for central nervous system indications.

AgeneBio's lead product candidate, AGB101, a tablet taken once a day, is being developed to slow the progression of Alzheimer's disease from the time patients and their family members begin to notice issues with memory. This stage of Alzheimer's, called amnestic mild cognitive impairment, or aMCI, precedes the point where a patient experiences dementia and may be the ideal time to intervene with advancing disease process. There is compelling evidence that the part of the brain critical to creating new memories, the hippocampus, becomes overactive in patients with early Alzheimer's leading to decreased brain function and worsening of Alzheimer's symptoms. AGB101 slows activity in the hippocampus to restore normal brain function.

"The looming challenge of an aging population confronted by Alzheimer's is one of the largest and most frightening public health issues on the horizon, presenting a significant challenge and opportunity for companies like AgeneBio," said McLaughlin. "This is an exciting time to be joining the AgeneBio team as the company prepares to initiate a large-scale Phase II/III clinical trial for AGB101 in 2015."

Pending the results of a two year, large-scale clinical trial expected to be initiated by mid-2015 and subsequent regulatory submission, AGB101 could be the first FDA approved product indicated to slow the progression of Alzheimer's disease while improving patient memory.

About AgeneBio, Inc.

AgeneBio is developing therapeutics with the potential to preserve and restore cognitive function affected by a number of neurodegenerative diseases. AgeneBio's lead product candidate, AGB101, is being developed to slow progression of Alzheimer's disease and improve patient memory. Results from a Phase II study of AGB101 published in 2012 demonstrated restoration of normal brain function and improvement in memory in patients treated with AGB101 compared to placebo. The company is planning to initiate a Phase II/III clinical trial in mid-2015. Pending clinical trial results and FDA approval, AGB101 has the potential to be the first Alzheimer's therapeutic to not only improve memory but also to slow the progression of Alzheimer's disease.

The company also has a novel GABAA a5 small molecule program in late discovery stage with potential to address unmet needs for several diseases of the central nervous system including Alzheimer's disease, autism, and schizophrenia. The technology and patents behind AgeneBio's pipeline were discovered and initially developed by researchers at Johns Hopkins University, including the company's founder and chief scientific officer, Michela Gallagher, PhD.

Media Contact:
Hilary Lefebvre
Email Contact
(212) 300-4929

More Stories By Marketwired .

Copyright © 2009 Marketwired. All rights reserved. All the news releases provided by Marketwired are copyrighted. Any forms of copying other than an individual user's personal reference without express written permission is prohibited. Further distribution of these materials is strictly forbidden, including but not limited to, posting, emailing, faxing, archiving in a public database, redistributing via a computer network or in a printed form.

Latest Stories
SYS-CON Events announced today that Datera, that offers a radically new data management architecture, has been named "Exhibitor" of SYS-CON's 21st International Cloud Expo ®, which will take place on Oct 31 - Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. Datera is transforming the traditional datacenter model through modern cloud simplicity. The technology industry is at another major inflection point. The rise of mobile, the Internet of Things, data storage and Big...
As many know, the first generation of Cloud Management Platform (CMP) solutions were designed for managing virtual infrastructure (IaaS) and traditional applications. But that’s no longer enough to satisfy evolving and complex business requirements. In his session at 21st Cloud Expo, Scott Davis, Embotics CTO, will explore how next-generation CMPs ensure organizations can manage cloud-native and microservice-based application architectures, while also facilitating agile DevOps methodology. He wi...
When you focus on a journey from up-close, you look at your own technical and cultural history and how you changed it for the benefit of the customer. This was our starting point: too many integration issues, 13 SWP days and very long cycles. It was evident that in this fast-paced industry we could no longer afford this reality. We needed something that would take us beyond reducing the development lifecycles, CI and Agile methodologies. We made a fundamental difference, even changed our culture...
WebRTC is the future of browser-to-browser communications, and continues to make inroads into the traditional, difficult, plug-in web communications world. The 6th WebRTC Summit continues our tradition of delivering the latest and greatest presentations within the world of WebRTC. Topics include voice calling, video chat, P2P file sharing, and use cases that have already leveraged the power and convenience of WebRTC.
In his opening keynote at 20th Cloud Expo, Michael Maximilien, Research Scientist, Architect, and Engineer at IBM, discussed the full potential of the cloud and social data requires artificial intelligence. By mixing Cloud Foundry and the rich set of Watson services, IBM's Bluemix is the best cloud operating system for enterprises today, providing rapid development and deployment of applications that can take advantage of the rich catalog of Watson services to help drive insights from the vast t...
For financial firms, the cloud is going to increasingly become a crucial part of dealing with customers over the next five years and beyond, particularly with the growing use and acceptance of virtual currencies. There are new data storage paradigms on the horizon that will deliver secure solutions for storing and moving sensitive financial data around the world without touching terrestrial networks. In his session at 20th Cloud Expo, Cliff Beek, President of Cloud Constellation Corporation, d...
Most companies are adopting or evaluating container technology - Docker in particular - to speed up application deployment, drive down cost, ease management and make application delivery more flexible overall. As with most new architectures, this dream takes a lot of work to become a reality. Even when you do get your application componentized enough and packaged properly, there are still challenges for DevOps teams to making the shift to continuous delivery and achieving that reduction in cost ...
Historically, some banking activities such as trading have been relying heavily on analytics and cutting edge algorithmic tools. The coming of age of powerful data analytics solutions combined with the development of intelligent algorithms have created new opportunities for financial institutions. In his session at 20th Cloud Expo, Sebastien Meunier, Head of Digital for North America at Chappuis Halder & Co., discussed how these tools can be leveraged to develop a lasting competitive advantage ...
The question before companies today is not whether to become intelligent, it’s a question of how and how fast. The key is to adopt and deploy an intelligent application strategy while simultaneously preparing to scale that intelligence. In her session at 21st Cloud Expo, Sangeeta Chakraborty, Chief Customer Officer at Ayasdi, will provide a tactical framework to become a truly intelligent enterprise, including how to identify the right applications for AI, how to build a Center of Excellence to ...
From 2013, NTT Communications has been providing cPaaS service, SkyWay. Its customer’s expectations for leveraging WebRTC technology are not only typical real-time communication use cases such as Web conference, remote education, but also IoT use cases such as remote camera monitoring, smart-glass, and robotic. Because of this, NTT Communications has numerous IoT business use-cases that its customers are developing on top of PaaS. WebRTC will lead IoT businesses to be more innovative and address...
SYS-CON Events announced today that CA Technologies has been named "Platinum Sponsor" of SYS-CON's 21st International Cloud Expo®, which will take place October 31-November 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. CA Technologies helps customers succeed in a future where every business - from apparel to energy - is being rewritten by software. From planning to development to management to security, CA creates software that fuels transformation for companies in the applic...
Blockchain is a shared, secure record of exchange that establishes trust, accountability and transparency across business networks. Supported by the Linux Foundation's open source, open-standards based Hyperledger Project, Blockchain has the potential to improve regulatory compliance, reduce cost as well as advance trade. Are you curious about how Blockchain is built for business? In her session at 21st Cloud Expo, René Bostic, Technical VP of the IBM Cloud Unit in North America, will discuss th...
Recently, IoT seems emerging as a solution vehicle for data analytics on real-world scenarios from setting a room temperature setting to predicting a component failure of an aircraft. Compared with developing an application or deploying a cloud service, is an IoT solution unique? If so, how? How does a typical IoT solution architecture consist? And what are the essential components and how are they relevant to each other? How does the security play out? What are the best practices in formulating...
Given the popularity of the containers, further investment in the telco/cable industry is needed to transition existing VM-based solutions to containerized cloud native deployments. The networking architecture of the solution isolates the network traffic into different network planes (e.g., management, control, and media). This naturally makes support for multiple interfaces in container orchestration engines an indispensable requirement.
In his session at @ThingsExpo, Arvind Radhakrishnen discussed how IoT offers new business models in banking and financial services organizations with the capability to revolutionize products, payments, channels, business processes and asset management built on strong architectural foundation. The following topics were covered: How IoT stands to impact various business parameters including customer experience, cost and risk management within BFS organizations.